Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Life Sciences
New life sciences study findings have been reported by researchers at University of Chicago
May 21st, 2008
A new study, 'IFN-gamma- and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers,' is now available. "Tumors elicit antitumor immune responses, but over time they evolve and can escape immune control through various mechanisms, including the loss of the antigen to which the response is directed. The escape of antigen-loss variants (ALVs) is a major obstacle to T cell-based immunotherapy for cancer," scientists writing in the Journal of Clinical Investigation report. "However, cancers can be cured if both the number of CTLs and the expression of antigen are high enough to allow targeting of not only tumor cells, but also the...
Source: Immunotherapy Weekly (2008-05-21)
|
